Rinvoq vs Entyvio for UC: What to Compare Before Switching

If you are comparing Rinvoq vs Entyvio for ulcerative colitis, or UC, begin with why your team is considering a change. Rinvoq is an oral Janus kinase inhibitor, while Entyvio is a biologic that blocks the integrin receptor α4β7, as described in the ACG Rinvoq review and Entyvio prescribing information. The comparison below can help you prepare a focused conversation.

Comparing the treatment routine

Think through where treatment would happen, how it would fit your week and what support you would want. Bring those preferences to the appointment alongside questions about the medicine itself. These adult UC schedules provide a starting point for that discussion.

Treatment	Initial treatment	Ongoing treatment
Rinvoq	45 mg orally daily for eight weeks	15 mg daily; 30 mg may be considered for refractory, severe or extensive disease
Entyvio	300 mg intravenously at weeks 0 and 2	From week 6, 300 mg intravenously every eight weeks or 108 mg under the skin every two weeks

Ask the prescribing team to identify the exact option being proposed and provide its instructions. Write down who will arrange appointments or training, which pharmacy to contact and where questions should go. Do that before reorganizing your calendar around a possible switch.

What effectiveness studies actually compare

U-ACHIEVE and U-ACCOMPLISH evaluated upadacitinib against placebo for eight-week induction, and the program included a separate maintenance trial, according to ACG review of the UC trial program.

In Entyvio's intravenous induction trial, clinical response at week 6 occurred in 47% of treated patients versus 26% receiving placebo, while clinical remission occurred in 17% versus 5%, according to Entyvio UC trial endpoints.

The outcome matters: response and remission are distinct trial measures, and a study's assessment week does not by itself establish which medicine acts faster. That is an interpretation of the differing endpoints and schedules in the upadacitinib program and Entyvio trial.

The AGA guideline also identifies differences in trial designs as a limitation on robust comparisons of longer-term outcomes, according to AGA discussion of comparative evidence.

Ask your clinician which outcome is most relevant to the recommendation and whether the evidence describes people with a treatment history similar to yours. Keep a note of the answer beside any quoted percentage.

Previous treatment changes the comparison

For adults previously exposed to advanced therapies, particularly tumor necrosis factor antagonists, the AGA places upadacitinib in a higher-efficacy group and vedolizumab in a lower-efficacy group; this is a conditional recommendation based on low-certainty evidence, according to AGA guidance after advanced-therapy exposure.

Rinvoq's current US indication includes inadequate response or intolerance to a tumor necrosis factor blocker, with a previous-systemic-therapy provision when those blockers are clinically inadvisable, according to Rinvoq UC eligibility.

Ask how those recommendations apply to your situation. If you are considering switching from Entyvio to Rinvoq, describe why the switch has come up: an unresolved symptom, a test result, a treatment problem or a practical concern. Ask which concern the proposed change is intended to address. Write down both the recommendation and the reason for it, and request clarification if either remains unclear. Bring your previous treatment dates if available.

Safety questions to raise before deciding

The FDA requires JAK-inhibitor warnings about serious cardiovascular events, cancer, blood clots and death, with the class-warning decision based on a tofacitinib rheumatoid arthritis safety trial, according to FDA JAK safety communication.

Smoking history and previous heart problems, stroke or blood clots are factors the FDA advises patients to discuss, according to FDA advice for patients.

Entyvio's precautions include infections, serious allergic reactions and liver injury, according to Entyvio warnings and precautions.

Rinvoq requires consideration of infection screening and laboratory monitoring, and its label discourages combining it with biological therapies for UC, according to Rinvoq precautions and limitations.

Ask for an individualized explanation of the safety trade-offs. Take your medication list to the appointment and ask which tests, vaccinations or follow-up visits your team wants arranged. Request written answers about who will review results and what should prompt a call. Make sure you understand the contact plan before leaving.

Leave with a clear switching discussion

Use a short written agenda to keep the visit focused. Start with the reason for considering another medicine and your priorities for the next few months. Then ask what the prescriber wants you to do next and when the decision will be reviewed. If there are unresolved questions, label them as such rather than guessing the answer afterward.

Ask the team to provide the actual medication plan, including what happens to your current prescription. Request a named contact for questions about appointments, pharmacy coordination or instructions that seem inconsistent. Keep this information together with your treatment history.

Finish by repeating the plan back in your own words. For example: “We have discussed this option, these questions remain open, and this is the next appointment.” That gives you an opportunity to correct misunderstandings before making arrangements or acting on incomplete instructions.